Three COVID-19 Drugs Clear UK Funding Hurdle But Olumiant No Longer In The Running
Executive Summary
NICE says it is the first health technology assessment body to look at the non-pandemic use of COVID-19 treatments. It is also planning to launch a consultation on a new process for updating its recommendations on such products with a view to making them available more quickly if new variants emerge.
You may also be interested in...
UK’s NICE Says No To AstraZeneca’s Evusheld Amid ‘Rapidly Changing’ COVID-19 landscape
NICE says that limitations in the evidence for Evusheld make it difficult to produce a reliable cost-effectiveness estimate.
Lilly Pulls EU Approval Application For Olumiant In COVID-19
The European Medicines Agency says it does not have enough data to justify the approval of Olumiant for hospitalized COVID-19 patients. The marketing authorization application for another product, Reata’s Imbarkyd for chronic kidney disease, has also been withdrawn.
England OKs Routine Funding For Three COVID-19 Treatments But Rejects Five Others
The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.